Please login to the form below

Not currently logged in
Email:
Password:

Juno

This page shows the latest Juno news and features for those working in and with pharma, biotech and healthcare.

Janssen’s CAR-T gains PRIME status in Europe

Janssen’s CAR-T gains PRIME status in Europe

Bluebird Bio and Celgene and currently seen as the frontrunners with their late-stage CAR-T candidate bb21217, while Celgene has a similar challenger in development with Juno.

Latest news

More from news
Approximately 11 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Celgene and Juno hope to crash the party soon with JCAR017, armed with positive data in diffuse large B-cell lymphoma (DLBCL).

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    $9bn  acquisition of Juno.

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch November 2016 Deal Watch November 2016

    Winding back two years, Juno enjoyed the biggest Nasdaq IPO of 2014 raising around $265m at $24 per share. ... At the end of this November Juno shares were trading at around $20 per share and to date they have not recovered.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report directly to Hans Bishop, Juno’s president ... She said: “I am delighted to join Juno, a company that reflects my

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics